CN102076358B - 新颖的佐剂组合物 - Google Patents

新颖的佐剂组合物 Download PDF

Info

Publication number
CN102076358B
CN102076358B CN200980124560.5A CN200980124560A CN102076358B CN 102076358 B CN102076358 B CN 102076358B CN 200980124560 A CN200980124560 A CN 200980124560A CN 102076358 B CN102076358 B CN 102076358B
Authority
CN
China
Prior art keywords
vaccine
virus
compositions
adjuvant
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200980124560.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN102076358A (zh
Inventor
克多·马丁·巴吉
泰德·艾伦·奇尔德斯
保罗·约瑟夫·多米诺斯基
理查德·李·克莱博斯
拉玛萨米·曼娜·曼南
玛丽·凯瑟琳·奥尔森
詹姆斯·理查德·汤普森
里斯尼·达米卡·维拉特纳
罗伯特·约翰·小燕西
张树成
桑吉塔·米蒂瑞塔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zoetis Services LLC
Original Assignee
Pfizer Ltd Great Britain
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd Great Britain, Pfizer Corp SRL filed Critical Pfizer Ltd Great Britain
Priority to CN201510098559.7A priority Critical patent/CN104758929B/zh
Priority to CN201410197979.6A priority patent/CN104001169B/zh
Priority to CN201410198333.XA priority patent/CN104001170B/zh
Publication of CN102076358A publication Critical patent/CN102076358A/zh
Application granted granted Critical
Publication of CN102076358B publication Critical patent/CN102076358B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/012—Coccidia antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12351—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24351—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
CN200980124560.5A 2008-06-27 2009-06-24 新颖的佐剂组合物 Active CN102076358B (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN201510098559.7A CN104758929B (zh) 2008-06-27 2009-06-24 新颖的佐剂组合物
CN201410197979.6A CN104001169B (zh) 2008-06-27 2009-06-24 新颖的佐剂组合物
CN201410198333.XA CN104001170B (zh) 2008-06-27 2009-06-24 新颖的佐剂组合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US7623208P 2008-06-27 2008-06-27
US61/076,232 2008-06-27
US21455709P 2009-04-24 2009-04-24
US61/214,557 2009-04-24
PCT/IB2009/052724 WO2009156960A2 (en) 2008-06-27 2009-06-24 Novel adjuvant compositions

Related Child Applications (3)

Application Number Title Priority Date Filing Date
CN201510098559.7A Division CN104758929B (zh) 2008-06-27 2009-06-24 新颖的佐剂组合物
CN201410197979.6A Division CN104001169B (zh) 2008-06-27 2009-06-24 新颖的佐剂组合物
CN201410198333.XA Division CN104001170B (zh) 2008-06-27 2009-06-24 新颖的佐剂组合物

Publications (2)

Publication Number Publication Date
CN102076358A CN102076358A (zh) 2011-05-25
CN102076358B true CN102076358B (zh) 2016-08-17

Family

ID=41445049

Family Applications (4)

Application Number Title Priority Date Filing Date
CN200980124560.5A Active CN102076358B (zh) 2008-06-27 2009-06-24 新颖的佐剂组合物
CN201410198333.XA Active CN104001170B (zh) 2008-06-27 2009-06-24 新颖的佐剂组合物
CN201510098559.7A Active CN104758929B (zh) 2008-06-27 2009-06-24 新颖的佐剂组合物
CN201410197979.6A Active CN104001169B (zh) 2008-06-27 2009-06-24 新颖的佐剂组合物

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN201410198333.XA Active CN104001170B (zh) 2008-06-27 2009-06-24 新颖的佐剂组合物
CN201510098559.7A Active CN104758929B (zh) 2008-06-27 2009-06-24 新颖的佐剂组合物
CN201410197979.6A Active CN104001169B (zh) 2008-06-27 2009-06-24 新颖的佐剂组合物

Country Status (29)

Country Link
US (6) US8580280B2 (enExample)
EP (4) EP3725328A3 (enExample)
JP (5) JP5659332B2 (enExample)
KR (1) KR101333852B1 (enExample)
CN (4) CN102076358B (enExample)
AR (1) AR072378A1 (enExample)
AU (1) AU2009263759B2 (enExample)
BR (2) BR122021025097B1 (enExample)
CA (3) CA2960734C (enExample)
CL (1) CL2010001360A1 (enExample)
CO (1) CO6331297A2 (enExample)
CY (2) CY1117650T1 (enExample)
DK (2) DK2310046T3 (enExample)
ES (2) ES2728949T3 (enExample)
HR (1) HRP20190876T1 (enExample)
HU (2) HUE043493T2 (enExample)
LT (1) LT3056214T (enExample)
ME (1) ME01199B (enExample)
MX (6) MX344311B (enExample)
NZ (5) NZ602945A (enExample)
PH (2) PH12014501835A1 (enExample)
PL (2) PL3056214T3 (enExample)
PT (1) PT3056214T (enExample)
RU (1) RU2510280C2 (enExample)
SI (2) SI3056214T1 (enExample)
TW (4) TWI622401B (enExample)
UY (1) UY31942A (enExample)
WO (1) WO2009156960A2 (enExample)
ZA (1) ZA201007835B (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8444989B1 (en) * 2008-04-18 2013-05-21 Boehringer Ingelheim Vetmedica Gmbh One dose vaccination against mycoplasma infections of pigs
EP3725328A3 (en) * 2008-06-27 2020-12-23 Zoetis Services LLC Novel adjuvant compositions
TWI351288B (en) * 2008-07-04 2011-11-01 Univ Nat Pingtung Sci & Tech Cpg dna adjuvant in avian vaccines
CA2745096C (en) 2008-12-09 2013-11-05 Coley Pharmaceutical Group, Inc. Immunostimulatory oligonucleotides
US8552165B2 (en) * 2008-12-09 2013-10-08 Heather Davis Immunostimulatory oligonucleotides
US9878036B2 (en) * 2009-08-12 2018-01-30 Sigmoid Pharma Limited Immunomodulatory compositions comprising a polymer matrix and an oil phase
FR2957803B1 (fr) * 2010-03-24 2012-06-01 Soc Dexploitation De Produits Pour Les Industries Chimiques Seppic Diluants adjuvants de vaccins vivants pour maladies porcines
CA2800158C (en) 2010-05-28 2020-07-21 Coley Pharmaceutical Group, Inc. Vaccines comprising cholesterol and cpg as sole adjuvant-carrier molecules
CA2836805C (en) * 2011-06-10 2023-03-07 Novartis Ag Bovine vaccines and methods
PT2750683T (pt) 2011-10-03 2018-06-26 Mx Adjuvac Ab Nanopartículas, processo de preparação e seu uso como transportadores para moléculas hidrofóbicas anfipáticas no domínio da medicina, incluindo tratamento de cancro e compostos relacionados a alimentos
WO2013138334A1 (en) * 2012-03-12 2013-09-19 Advanced Bioadjuvants, Llc Adjuvant and vaccine compositions
UA121193C2 (uk) 2012-12-28 2020-04-27 Бьорінгер Інгельхайм Ветмедіка Гмбх Спосіб одержання імуногенної композиції проти мікоплазми
KR102355614B1 (ko) 2012-12-28 2022-01-27 베링거잉겔하임베트메디카게엠베하 마이코플라스마 항원을 포함하는 면역원성 조성물
CN103127495B (zh) * 2013-01-28 2015-04-08 重庆市畜牧科学院 二联灭活苗的制剂及其制备方法
US20160199482A1 (en) * 2013-09-05 2016-07-14 Zoetis Services Llc Hendra and nipah virus g glycoprotein immunogenic compositions
WO2015042369A2 (en) * 2013-09-19 2015-03-26 Zoetis Llc Oil-based adjuvants
EP3057613A1 (en) 2013-10-17 2016-08-24 Zoetis Services LLC Methods and compositions for treatment of s. equi infection
CN105899199A (zh) * 2013-11-26 2016-08-24 硕腾服务有限责任公司 诱导免疫应答的组合物
MX388527B (es) * 2014-11-26 2025-03-20 Huvepharma Inc Composiciones adyuvantes y metodos relacionados.
US10195261B2 (en) 2014-11-26 2019-02-05 VaxLiant, LLC Adjuvant compositions and related methods
CN114699518B (zh) * 2015-01-16 2024-07-02 硕腾服务有限责任公司 口蹄疫疫苗
CA2979556C (en) * 2015-03-24 2023-07-18 VaxLiant, LLC Adjuvant compositions and related methods
CN104771754B (zh) * 2015-04-02 2018-02-13 武汉科前生物股份有限公司 一种猪圆环病毒2型灭活疫苗水性佐剂及应用
CN106267183B (zh) * 2015-06-09 2023-02-28 普莱柯生物工程股份有限公司 含有佐剂的活疫苗组合物及其制备方法和应用
CN106344920B (zh) * 2015-07-16 2020-11-27 普莱柯生物工程股份有限公司 一种疫苗用佐剂及其应用
US10456459B2 (en) 2015-07-20 2019-10-29 Zoetis Services Llc Liposomal adjuvant compositions
AR105393A1 (es) * 2015-07-20 2017-09-27 Zoetis Services Llc Composiciones adyuvantes liposómicas
SG10201913547YA (en) * 2015-10-19 2020-02-27 Cadila Healthcare Ltd New adjuvant and vaccine composition containing the same
EP3402878A1 (en) 2016-01-11 2018-11-21 Zoetis Services LLC Novel cross protective vaccine compositions for porcine epidemic diarrhea virus
US11013798B2 (en) 2016-03-21 2021-05-25 South Dakota Board Of Regents Orf virus-based platform for vaccine delivery
EP3463446A1 (en) 2016-06-02 2019-04-10 Zoetis Services LLC Vaccine against infectious bronchitis
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
GB201703529D0 (en) 2017-03-06 2017-04-19 Cambridge Entpr Ltd Vaccine composition
US10092604B1 (en) * 2017-12-21 2018-10-09 Bioceuticals Pte. Ltd. Methods for treatment of skin infectious diseases using microorganisms
BR112020017715A2 (pt) 2018-03-16 2020-12-29 Zoetis Services Llc Vacinas de peptídeo contra interleucina-31
CN108853493A (zh) * 2018-07-26 2018-11-23 中国人民解放军陆军军医大学 麦冬皂苷d及其纳米乳在制备疫苗佐剂中的应用
US11046734B2 (en) 2018-07-27 2021-06-29 Research Development Foundation Chimeric immunogenic polypeptides
EP3849521A1 (en) 2018-09-14 2021-07-21 Massachusetts Institute Of Technology Nanoparticle vaccine adjuvant and methods of use thereof
CN109675028A (zh) * 2019-03-01 2019-04-26 龙阔（苏州）生物工程有限公司 疫苗佐剂及其制备方法和应用及猪繁殖与呼吸综合征疫苗
US20220356231A1 (en) * 2019-07-12 2022-11-10 Research Development Foundation Ehrlichia vaccines and immunogenic compositions
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
AU2021292703A1 (en) * 2020-06-19 2023-02-09 Kimberly-Clark Worldwide, Inc. Saponin containing extracts prepared from hesperaloe useful in the treatment of non-human animals
CA3182454A1 (en) * 2020-06-19 2021-12-23 Thomas G. Shannon Animal feed composition for reducing ammonia production
TWI884296B (zh) * 2020-08-11 2025-05-21 美商碩騰服務公司 抗冠狀病毒疫苗
CN114848807A (zh) * 2021-02-04 2022-08-05 洛阳赛威生物科技有限公司 一种蜂胶佐剂组合物、及其制备方法以及应用
WO2023056117A1 (en) * 2021-10-02 2023-04-06 Massachusetts Institute Of Technology Synergistic combination of alum and non-liposome, non-micelle particle vaccine adjuvants
CN120712079A (zh) * 2023-02-16 2025-09-26 瓦希纳诺公司 包含用于在没有任何佐剂的情况下经由阳离子多糖纳米颗粒递送灭活的完整细菌的系统的疫苗组合物
US12226468B2 (en) 2023-06-26 2025-02-18 Research Development Foundation Immunoreactive peptides
CN116747312B (zh) * 2023-07-21 2025-08-08 辽宁成大生物股份有限公司 一种疫苗冻干保护剂、制剂及制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003003941A3 (en) * 2001-07-02 2004-07-29 Pfizer Prod Inc One dose vaccination with mycoplasma hyopneumoniae
CN1835767A (zh) * 2003-01-29 2006-09-20 辉瑞产品公司 对抗支气管败血性博德特氏杆菌的犬疫苗

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4264587A (en) * 1979-08-01 1981-04-28 Pedersen Niels C Vaccine for preventing persistent feline leukemia viremia in cats
NZ221306A (en) * 1986-08-15 1990-02-26 Commw Scient Ind Res Org 2-component immunoadjuvant comprising a mycobacterial free immunoadjuvant oil and a polycationic polyelectrolyte immunoadjuvant and vaccines thereof
US5084269A (en) 1986-11-06 1992-01-28 Kullenberg Fred W Adjuvant for dose treatment with antigens
ATE60999T1 (de) 1986-12-19 1991-03-15 Duphar Int Res Dimethyldioctadecylammoniumbromid enthaltende stabilisierte adjuvanssuspension.
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) * 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
RU1615918C (ru) 1989-05-22 1995-07-09 Всероссийский научно-исследовательский институт защиты животных Адъювант
EP0621893A4 (en) * 1992-01-06 1995-07-12 Smithkline Beecham Corp Vaccines against the cat's leukemia virus.
ZA936095B (en) 1992-08-21 1994-03-14 Univ Melbourne Cytokine applications.
US6764682B1 (en) 1994-06-16 2004-07-20 Aventis Pasteur Limited Adjuvant compositions containing more than one adjuvant
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6846489B1 (en) * 1995-04-25 2005-01-25 Smithkline Beecham Biologicals S.A. Vaccines containing a saponin and a sterol
ES2241042T3 (es) 1996-10-11 2005-10-16 The Regents Of The University Of California Conjugados de polinucleotido inmunoestimulador/ molecula inmunomoduladora.
EP0855184A1 (en) 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
EP1039935A4 (en) 1997-02-28 2005-04-27 Univ Iowa Res Found USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
WO1998040100A1 (en) 1997-03-10 1998-09-17 Ottawa Civic Loeb Research Institute USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
BR9809426A (pt) 1997-04-30 2000-06-13 Merieux Oravax Composição de vacina anti-helicobacter para uso pela via sistêmica subdiafragmática e método de imunização mucosal/parenteral combinado
DE69841002D1 (de) 1997-05-14 2009-09-03 Univ British Columbia Hochwirksame verkapselung von nukleinsäuren in lipidvesikeln
ATE432348T1 (de) 1997-06-06 2009-06-15 Univ California Inhibitoren von immunstimulatorischen dna sequenz aktivität
KR20010024245A (ko) * 1997-10-20 2001-03-26 조지 제이. 리코스 네오스포라 백신
EP0953641A3 (en) * 1998-03-26 2002-03-13 Pfizer Products Inc. Polynucleotide molecules encoding neospora proteins
NZ508650A (en) 1998-05-14 2003-05-30 Coley Pharm Gmbh Regulating hematopoiesis using unmethylated C and G CpG-oligonucleotides with a phosphorothioate modification
ES2272069T3 (es) 1998-05-22 2007-04-16 Ottawa Health Research Institute Metodos y productos para inducir inmunidad en mucosas.
US20040247662A1 (en) 1998-06-25 2004-12-09 Dow Steven W. Systemic immune activation method using nucleic acid-lipid complexes
DE69929444T2 (de) 1998-08-10 2006-09-28 Antigenics Inc., Woburn Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung
AU769539B2 (en) 1999-01-29 2004-01-29 Zoetis Services Llc Adjuvants for use in vaccines
EP1574210B1 (en) 1999-02-26 2016-04-06 Novartis Vaccines and Diagnostics, Inc. Microemulsions with adsorbed macromolecules
ATE529130T1 (de) 1999-04-08 2011-11-15 Intercell Usa Inc Trockenformulierung für transkutane immunisierung
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
DK1187629T3 (da) 1999-04-19 2005-01-17 Glaxosmithkline Biolog Sa Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
DE60013591T2 (de) 1999-04-29 2005-02-03 Coley Pharmaceutical Gmbh Screening nach modulatoren der funktion von immunstimulatorischer dna
DE60131430T2 (de) 2000-01-14 2008-10-16 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Oligodeoxynukleotide und ihre verwendung zur induktion einer immunreaktion
CA2396871A1 (en) 2000-01-20 2001-12-20 Ottawa Health Research Institute Immunostimulatory nucleic acids for inducing a th2 immune response
AT409085B (de) 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
ES2248283T3 (es) 2000-02-21 2006-03-16 Pharmexa A/S Nuevo procedimiento para reducir los niveles de amiloide.
AU2001257366B2 (en) 2000-05-01 2006-03-16 Idera Pharmaceuticals, Inc. Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
AT410173B (de) 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
GB0025577D0 (en) 2000-10-18 2000-12-06 Smithkline Beecham Biolog Vaccine
ES2307568T3 (es) 2000-12-08 2008-12-01 Coley Pharmaceutical Gmbh Acidos nucleicos de tipo cpg y metodos de uso de los mismos.
US7244438B2 (en) 2001-01-05 2007-07-17 Intercell Ag Uses for polycationic compounds
US7713942B2 (en) 2001-04-04 2010-05-11 Nordic Vaccine Technology A/S Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides
EP1372528B1 (en) 2001-04-05 2013-01-02 Novartis Vaccines and Diagnostics, Inc. Mucosal boosting following parenteral priming
US7105495B2 (en) 2001-04-30 2006-09-12 Idera Pharmaceuticals, Inc. Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
CN1526016A (zh) 2001-05-21 2004-09-01 �����ɷ� 稳定核酸的方法
WO2002102307A2 (en) * 2001-06-15 2002-12-27 Ribapharm Nucleoside vaccine adjuvants
JP2004537543A (ja) * 2001-07-02 2004-12-16 ファイザー・プロダクツ・インク マイコプラズマ・ハイオニューモニエ・ワクチンおよび牛におけるマイコプラズマ・ボビス低減方法
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
WO2003025119A2 (en) 2001-08-03 2003-03-27 Medarex, Inc. Compositions comprising immunostimulatory oligonucleotides and uses thereof to enhance fc receptor-mediated immunotherapies
AU2002326561B2 (en) 2001-08-07 2008-04-03 Dynavax Technologies Corporation Immunomodulatory compositions, formulations, and methods for use thereof
US20030138434A1 (en) 2001-08-13 2003-07-24 Campbell Robert L. Agents for enhancing the immune response
IL160157A0 (en) 2001-08-17 2004-07-25 Coley Pharm Group Inc Combination motif immune stimulation oligonucleotides with improved activity
JP2005500845A (ja) 2001-08-28 2005-01-13 ファイザー・プロダクツ・インク マイコプラズマ・ボビスチャレンジモデル並びにマイコプラズマ・ボビスの投与方法及び肺炎性肺病変の誘発方法
ES2335979T3 (es) 2001-09-14 2010-04-07 Cytos Biotechnology Ag Empaquetamiento de cpg inmunoestimuladores en particulas similares a virus: metodo de preparacion y su uso.
US20030119774A1 (en) 2001-09-25 2003-06-26 Marianna Foldvari Compositions and methods for stimulating an immune response
GB0123580D0 (en) * 2001-10-01 2001-11-21 Glaxosmithkline Biolog Sa Vaccine
CA2471968C (en) 2001-10-06 2013-07-23 Merial Limited Immunostimulatory nucleic acids and use thereof
US7276489B2 (en) 2002-10-24 2007-10-02 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
JP2005516897A (ja) 2001-11-07 2005-06-09 イネックス ファーマシューティカルズ コーポレイション 改善された粘膜のワクチン及びその使用方法
EP1450821A1 (en) 2001-12-07 2004-09-01 Intercell AG Immunostimulatory oligodeoxynucleotides
CA2474709A1 (en) 2002-02-04 2003-08-14 Biomira, Inc. Immunostimulatory, covalently lipidated oligonucleotides
US8088388B2 (en) 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
AU2003219810A1 (en) 2002-02-19 2003-09-09 Syntherica Corporation Compositions and methods for surrogate antibody modulation of an immune response and transport
EP1499187B1 (en) 2002-04-04 2015-06-17 Zoetis Belgium S.A. Immunostimulatory g,u-containing oligoribonucleotides
AU2003262379A1 (en) 2002-04-16 2003-11-03 Auburn University TRANSIENT AND/OR PERMANENT MODIFICATION OF SEXUAL BEHAVIOR AND/OR FERTILITY USING RECOMBINANT CHIMERIC GnRH
CA2483012C (en) 2002-04-22 2011-05-24 Bioniche Life Sciences Inc. Oligonucleotide compositions and their use for the modulation of immune responses
KR100456681B1 (ko) 2002-05-22 2004-11-10 주식회사 대웅 박테리아의 염색체 ｄｎａ 파쇄물과 비독성리포폴리사카라이드를 포함하는 면역강화 및 조절 조성물
CA2487452A1 (en) 2002-05-28 2003-12-04 Robinson Ramirez-Pineda A method for generating antigen-presenting cells
CA2388049A1 (en) 2002-05-30 2003-11-30 Immunotech S.A. Immunostimulatory oligonucleotides and uses thereof
SE0201701D0 (sv) 2002-06-05 2002-06-05 Gotovax Ab Treatment of epithelial tumors and infections
WO2003103586A2 (en) 2002-06-05 2003-12-18 Coley Pharmaceutical Group, Inc. Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory cpg nucleic acids
AU2003263963A1 (en) 2002-08-01 2004-02-23 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Method of treating inflammatory arthropathies with suppressors of cpg oligonucleotides
EP1565406A4 (en) 2002-11-05 2008-07-23 James Hardie Int Finance Bv PROCESS AND APPARATUS FOR PRODUCING CALCIUM SILICATE HYDRATE
AU2003900767A0 (en) * 2003-02-21 2003-03-13 St Vincent's Hospital Sydney Limited Idiotypic vaccine
CA2517839A1 (en) 2003-03-26 2004-10-07 Martin F. Bachmann Melan-a peptide analogue-virus-like-particle conjugates
CA2521051C (en) 2003-04-04 2012-03-20 Pfizer Products Inc. Microfluidized oil-in-water emulsions and vaccine compositions
SE0301998D0 (sv) * 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
GB0323965D0 (en) * 2003-10-13 2003-11-19 Glaxosmithkline Biolog Sa Immunogenic compositions
DE202005022108U1 (de) 2004-03-09 2013-11-12 Novartis Vaccines And Diagnostics, Inc. Influenza-Virus-Impfstoffe
KR20110132416A (ko) * 2004-04-05 2011-12-07 화이자 프로덕츠 인코포레이티드 미세유체화된 수중유 유화액 및 백신 조성물
EP1799252A4 (en) * 2004-10-06 2009-01-21 Agri Biotech Pty Ltd ANTIBODY PRODUCTION PROCESS
GB0426481D0 (en) * 2004-12-02 2005-01-05 Vaccine Technology Ltd Composition
WO2006106424A2 (en) * 2005-04-07 2006-10-12 Pharmacia & Upjohn Company Llc Formulations and process for production of bordetella bronchiseptica p68 antigen and vaccines
WO2006116458A2 (en) * 2005-04-26 2006-11-02 Coley Pharmaceutical Gmbh Modified oligoribonucleotide analogs with enhances immunostimulatory activity
JP4667507B2 (ja) * 2005-10-07 2011-04-13 ファイザー・プロダクツ・インク イヌインフルエンザを治療するワクチンおよび方法
EP1954252B1 (en) * 2005-12-02 2016-02-03 GlaxoSmithKline Biologicals SA Nanoparticles for use in immunogenic compositions
CN101379397A (zh) * 2006-01-26 2009-03-04 Hx诊断公司 H5亚型禽流感病毒血凝素蛋白的单克隆抗体或其结合活性片段及其用途
PL1991266T3 (pl) * 2006-01-26 2013-11-29 Zoetis Services Llc Nowe kompozycje adiuwantów glikolipidowych
NZ578380A (en) 2006-12-15 2012-04-27 Schering Plough Ltd Method for replicating influenza virus in culture
WO2008074487A2 (en) * 2006-12-19 2008-06-26 Novosom Ag Lipids and lipid assemblies comprising transfection enhancer elements
US20080292663A1 (en) 2007-05-22 2008-11-27 Gerber Jay D Adjuvant compositions and methods for delivering vaccines
CL2008001806A1 (es) 2007-06-20 2008-09-05 Wyeth Corp Composicion de vacuna en emulsion agua en aceite que comprende un antigeno y un adyuvante en la fase acuosa; y metodo de elaboracion.
EP3725328A3 (en) * 2008-06-27 2020-12-23 Zoetis Services LLC Novel adjuvant compositions
AU2010218752B2 (en) 2009-02-27 2015-05-28 Toray Industries, Inc. Immunogenic composition
US10456459B2 (en) * 2015-07-20 2019-10-29 Zoetis Services Llc Liposomal adjuvant compositions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003003941A3 (en) * 2001-07-02 2004-07-29 Pfizer Prod Inc One dose vaccination with mycoplasma hyopneumoniae
CN1835767A (zh) * 2003-01-29 2006-09-20 辉瑞产品公司 对抗支气管败血性博德特氏杆菌的犬疫苗

Also Published As

Publication number Publication date
HUE028921T2 (en) 2017-01-30
EP3725328A2 (en) 2020-10-21
JP2015143244A (ja) 2015-08-06
BR122021025097B1 (pt) 2022-07-26
CA2960734C (en) 2021-08-24
CN104001170B (zh) 2016-08-24
PH12014501835A1 (en) 2016-03-07
WO2009156960A2 (en) 2009-12-30
US20090324641A1 (en) 2009-12-31
CA2723786A1 (en) 2009-12-30
HK1201444A1 (zh) 2015-09-04
WO2009156960A3 (en) 2010-06-17
US20170304434A1 (en) 2017-10-26
RU2510280C2 (ru) 2014-03-27
MX375202B (es) 2025-03-06
US9662385B2 (en) 2017-05-30
JP2014111619A (ja) 2014-06-19
DK2310046T3 (da) 2016-04-25
LT3056214T (lt) 2019-06-10
HRP20190876T1 (hr) 2019-07-12
CA2723786C (en) 2020-04-28
UY31942A (es) 2010-01-29
BRPI0913954A2 (pt) 2021-04-06
RU2010149495A (ru) 2012-08-10
BRPI0913954B1 (pt) 2022-04-05
CA2960846A1 (en) 2009-12-30
HK1211870A1 (en) 2016-06-03
KR20110010817A (ko) 2011-02-07
CY1117650T1 (el) 2017-04-26
WO2009156960A9 (en) 2010-09-30
JP2014111620A (ja) 2014-06-19
JP5659332B2 (ja) 2015-01-28
US20190008953A1 (en) 2019-01-10
NZ602945A (en) 2014-05-30
TW201014601A (en) 2010-04-16
KR101333852B1 (ko) 2013-11-27
NZ621834A (en) 2015-10-30
TW201544122A (zh) 2015-12-01
CN104001169A (zh) 2014-08-27
DK3056214T3 (da) 2019-05-13
EP3056214B1 (en) 2019-04-03
PH12014501836A1 (en) 2016-03-07
ES2569907T3 (es) 2016-05-13
CA2960846C (en) 2020-08-25
AU2009263759A1 (en) 2009-12-30
JP6294938B2 (ja) 2018-03-14
MX349720B (es) 2017-08-09
US8580280B2 (en) 2013-11-12
US10238736B2 (en) 2019-03-26
US11896666B2 (en) 2024-02-13
CA2960734A1 (en) 2009-12-30
JP2011525911A (ja) 2011-09-29
CN104001169B (zh) 2016-03-23
AU2009263759B2 (en) 2013-06-06
ES2728949T3 (es) 2019-10-29
CN104758929A (zh) 2015-07-08
EP3725328A3 (en) 2020-12-23
EP3056214A1 (en) 2016-08-17
NZ589079A (en) 2012-11-30
JP5824538B2 (ja) 2015-11-25
MX2010014026A (es) 2011-02-15
CL2010001360A1 (es) 2011-04-08
SI3056214T1 (sl) 2019-06-28
TWI614027B (zh) 2018-02-11
US10940202B2 (en) 2021-03-09
PL3056214T3 (pl) 2019-09-30
TWI622400B (zh) 2018-05-01
TWI622401B (zh) 2018-05-01
PT3056214T (pt) 2019-06-12
EP3552625A1 (en) 2019-10-16
CO6331297A2 (es) 2011-10-20
HUE043493T2 (hu) 2019-08-28
TW201544121A (zh) 2015-12-01
US20140056940A1 (en) 2014-02-27
CN104001170A (zh) 2014-08-27
ZA201007835B (en) 2012-01-25
ME01199B (me) 2013-03-20
MX344311B (es) 2016-12-13
EP2310046A2 (en) 2011-04-20
AR072378A1 (es) 2010-08-25
US20210338810A1 (en) 2021-11-04
CN102076358A (zh) 2011-05-25
JP2017061484A (ja) 2017-03-30
JP5882370B2 (ja) 2016-03-09
JP6038211B2 (ja) 2016-12-07
CY1121789T1 (el) 2020-07-31
SI2310046T1 (sl) 2016-05-31
US20240358825A1 (en) 2024-10-31
MX368220B (es) 2019-09-24
MX2019011253A (es) 2019-11-01
PL2310046T3 (pl) 2016-09-30
TWI513464B (zh) 2015-12-21
NZ727616A (en) 2018-06-29
TW201540311A (zh) 2015-11-01
NZ709547A (en) 2017-01-27
EP2310046B1 (en) 2016-03-09
HK1201445A1 (en) 2015-09-04
CN104758929B (zh) 2018-05-25

Similar Documents

Publication Publication Date Title
US11896666B2 (en) Adjuvant compositions
AU2017201506B2 (en) Novel adjuvanat compositions
HK1211870B (en) Novel adjuvant compositions
HK1157240A (en) Novel adjuvant compositions
HK1157240B (en) Novel adjuvant compositions
HK1201445B (en) Novel adjuvant compositions

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1157240

Country of ref document: HK

ASS Succession or assignment of patent right

Owner name: AH USA 42 LLC

Free format text: FORMER OWNER: PFIZER LTD.

Effective date: 20130827

C41 Transfer of patent application or patent right or utility model
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: American New York

Applicant after: Pfizer Inc.

Address before: American New York

Applicant before: Ah USA 42 LLC

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: AH USA 42 LLC TO: SHUOTENG CO., LTD.

TA01 Transfer of patent application right

Effective date of registration: 20130827

Address after: American New York

Applicant after: Ah USA 42 LLC

Address before: American New York

Applicant before: PFIZER Ltd.

C53 Correction of patent of invention or patent application
CB03 Change of inventor or designer information

Inventor after: Gram Thomas Ding Baji

Inventor after: Zhang Shucheng

Inventor after: Sangeeta Mitirita

Inventor after: Taide Alan's Childers

Inventor after: This base of Borrow Joseph domino

Inventor after: Richard Li Kelaibosi

Inventor after: La Masa meter Man Namannan

Inventor after: Mary Catherine Mancur Olson

Inventor after: James Richard Tang Pusen

Inventor after: Li Sinida rice card Wella Tener

Inventor after: Robert John little Yan west

Inventor before: Gram Thomas Ding Baji

Inventor before: Zhang Shucheng

Inventor before: Taide Alan's Childers

Inventor before: This base of Borrow Joseph domino

Inventor before: Richard Li Kelaibosi

Inventor before: La Masa meter Man Namannan

Inventor before: Mary Catherine Mancur Olson

Inventor before: James Richard Tang Pusen

Inventor before: Li Sinida rice card Wella Tener

Inventor before: Robert John little Yan west

COR Change of bibliographic data

Free format text: CORRECT: INVENTOR; FROM: MARTIN BAGI CEDO ALAN CHILDERS TEDD JOSEPH DOMINOWSKI PAUL LEE KREBS RICHARD MANNAR MANNAN RAMASAMYC KATHRYN OLSEN MARY RICHARD THOMPSON JAMES DHAMMIKA WEERATNA RISINI JOHN YANCEY ROBERT JR ZHANG SHUCHENG TO: MARTIN BAGI CEDO ALAN CHILDERS TEDD JOSEPH DOMINOWSKI PAUL LEE KREBS RICHARD MANNAR MANNAN RAMASAMYC KATHRYN OLSEN MARY RICHARD THOMPSON JAMES DHAMMIKA WEERATNA RISINI JOHN YANCEY ROBERT JR ZHANG SHUCHENG SANGITA MITERITA

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1157240

Country of ref document: HK

TR01 Transfer of patent right

Effective date of registration: 20190125

Address after: New jersey, USA

Patentee after: Zoetis Services LLC

Address before: American New York

Patentee before: Pfizer Inc.

TR01 Transfer of patent right